CGTN: China achieves ‘major, decisive’ victory in COVID-19 response: CPC leadership
BEIJING, Feb. 17, 2023 /PRNewswire/ -- Over the past three years, China has always been putting people's lives and health first and adapting its COVID-19 response in light of the evolving situation, in efforts widely believed to have bought precious time for a smooth transition. The country has achieved a major and decisive victory in its COVID-19 prevention and control...
USANA’s Malaysia Market Awarded for Facial Serum
Company Receives Citta Bella magazine award for the second time KUALA LUMPUR, Malaysia, Feb. 17, 2023 /PRNewswire/ -- For the second year in a row, USANA Malaysia has been awarded the "Best Vitalizing Serum" by Citta Bella magazine for its Celavive Vitalizing Serum. This exclusive skincare staple is designed to restore a healthy,...
Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders
JIUQUAN, China, Feb. 17, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (the "Company" or Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of $0.05 per ordinary share, payable in cash on or about March 6, 2023, to shareholders of record on February 28, 2023. "Despite...
Terumo Blood and Cell Technologies’ IMUGARD Platelet Pooling Set Cleared by FDA
IMUGARD to Help Strained U.S. Platelet Supply Meet Growing Need LAKEWOOD, Colo., Feb. 17, 2023 /PRNewswire/ -- Today, Terumo Blood and Cell Technologies announces U.S. Food and Drug Administration (FDA) clearance and official launch of its IMUGARD® WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days. IMUGARD is the first...
GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS
Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe for New Zealand patients YONDELIS® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine SINGAPORE and AUCKLAND, New Zealand, Feb. 17, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that its portfolio therapy...
Dalton Announces Major Expansion in Commercial Sterile Manufacturing Capacity
TORONTO, Feb. 17, 2023 /PRNewswire/ -- Dalton Pharma Services today announced a major strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new state-of-the-art, fully automated cGMP sterile filling line with the flexibility to fill vials, syringes, and cartridges under isolator technology. The sterile fill line is fully integrated with a new cGMP...
Immuno Cure kick off Phase I Clinical Trial in Shenzhen
A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS HONG KONG, Feb. 16, 2023 /PRNewswire/ -- Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in PD-1-Enhanced DNA vaccines and immunotherapies, announced the kicking off of the Phase I Clinical Trial of ICVAX, a...
H/Advisors Public Affairs, Powered by Havas Health & You, to Launch Fully Integrated U.K./EU/U.S. Public Affairs Practice
BRUSSELS, Feb. 16, 2023 /PRNewswire/ -- To help brands and clients stay on the pulse of the world's rapidly changing political and regulatory health landscape, H/Advisors, the global strategic advisory offering of the Havas Network, today announced the launch of a fully integrated health care public affairs offering, H/Advisors Public Affairs. The...
Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B
HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the oral presentation at the 2023 annual meeting of the Asian Pacific Association for the Study of the Liver ("APASL Annual Meeting 2023") demonstrates that ASC22 (Envafolimab), a subcutaneous PD-L1 antibody, can achieve functional cure of chronic hepatitis B (CHB). The final...
Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck
HELSINGBORG, Sweden, Feb. 16, 2023 /PRNewswire/ -- AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. Merck will make an upfront cash payment of EUR 10 million to Aqilion. In addition, Aqilion is eligible to receive potential development and...
